Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CAPRNASDAQ:MBVXNASDAQ:ONTXNASDAQ:TRIL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$5.12+1.4%$5.50$2.68▼$8.22$161.28M3.99283,667 shs140,236 shsMBVXMabvax Therapeutics$0.38$0.10▼$2.55$213KN/A31,620 shs1,333 shsONTXOnconova Therapeutics$0.82$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics-9.01%-18.94%-25.63%+25.31%+19.39%MBVXMabvax Therapeutics0.00%0.00%0.00%0.00%0.00%ONTXOnconova Therapeutics0.00%0.00%+20.64%+44.71%+39.18%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPRCapricor Therapeutics0.7988 of 5 stars3.50.00.00.01.40.80.6MBVXMabvax TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONTXOnconova Therapeutics0.7108 of 5 stars3.53.00.00.00.00.00.0TRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics3.00Buy$24.00368.75% UpsideMBVXMabvax TherapeuticsN/AN/AN/AN/AONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideTRILTrillium TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest TRIL, ONTX, CAPR, and MBVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/1/2024CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$25.18M6.41N/AN/A$0.73 per share7.01MBVXMabvax TherapeuticsN/AN/AN/AN/AN/AN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00TRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$22.29M-$0.87N/A42.67N/A-88.52%-299.67%-45.54%5/9/2024 (Estimated)MBVXMabvax TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/AN/AONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)TRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/ALatest TRIL, ONTX, CAPR, and MBVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023CAPRCapricor Therapeutics-$0.23-$0.02+$0.21-$0.02$5.80 million$12.09 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/AMBVXMabvax TherapeuticsN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A1.631.63MBVXMabvax TherapeuticsN/AN/AN/AONTXOnconova TherapeuticsN/A2.792.79TRILTrillium TherapeuticsN/A19.8219.82OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%MBVXMabvax Therapeutics12.72%ONTXOnconova Therapeutics7.95%TRILTrillium Therapeutics87.15%Insider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics12.00%MBVXMabvax Therapeutics14.76%ONTXOnconova Therapeutics3.30%TRILTrillium Therapeutics9.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor TherapeuticsN/A31.50 million27.72 millionOptionableMBVXMabvax TherapeuticsN/A9.26 millionN/ANot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableTRIL, ONTX, CAPR, and MBVX HeadlinesSourceHeadlineCachet Bicycle shakes off COVIDbaytoday.ca - February 25 at 12:23 PMRejuvenate your look with a trip to Fourth Avenue Medical Aestheticschch.com - January 30 at 5:32 PMTTI apprehends motorists for illegal removal of clamps, hunt for four others underwaybulawayo24.com - January 30 at 5:32 PMBridgeBio raises $1.25bn, and other biotech financingspharmaphorum.com - January 19 at 7:18 AMRatio Therapeutics Raises $50M in Series B Financingprecisionmedicineonline.com - January 17 at 1:39 PMLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.combusinesswire.com - November 10 at 1:22 PMMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 8 at 1:30 AMThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast perioduk.finance.yahoo.com - July 31 at 9:03 AMRatio Therapeutics unveils new research and development facilitybiopharma-reporter.com - May 15 at 10:33 AMWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'msn.com - April 26 at 12:18 AMLeukemia Therapeutics Global Market Report 2023uk.finance.yahoo.com - April 4 at 10:35 AMRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merckfinance.yahoo.com - March 28 at 9:12 AMTrillium House, an affordable housing project in Warrenton, close to completiondailyastorian.com - January 10 at 12:26 AMFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinomanz.finance.yahoo.com - October 19 at 9:39 AMCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatmentseekingalpha.com - September 14 at 9:48 AMZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directorsnz.finance.yahoo.com - September 12 at 7:55 AMPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Neededseekingalpha.com - August 17 at 11:07 AMTTI reviews parking modelchronicle.co.zw - August 10 at 10:41 PMTTI working round the clock to configure its systemschronicle.co.zw - August 10 at 10:41 PMPfizer in advanced talks to buy firm making sickle cell drugspmnewsnigeria.com - August 7 at 3:57 AM10 Psychedelics CEOs To Pay Attention To In 2022markets.businessinsider.com - June 22 at 10:08 AMHighlights from ASCO Annual Meeting 2022healio.com - June 15 at 1:37 PMChlormethine gel may be more effective than ointment for mycosis fungoideshealio.com - May 27 at 4:34 PMPfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?edition.cnn.com - May 20 at 2:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCapricor TherapeuticsNASDAQ:CAPRCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Mabvax TherapeuticsNASDAQ:MBVXMabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Trillium TherapeuticsNASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.